A team led by Anita Shukla at Brown University developed a smart hydrogel wound dressing that releases antibiotics only when infection is present. The hydrogel sits on a wound under a bandage and is made of water and long polymer molecules linked by crosslinkers.
The researchers designed a crosslinker that breaks down when it encounters enzymes called beta-lactamases, which many harmful bacteria produce. When those enzymes are present, the hydrogel degrades and frees the antibiotic; when they are absent, the material keeps the drug trapped.
Laboratory petri dish tests showed enzyme-specific degradation and no release with harmless bacteria. In mice, a single application cleared a bacterial infection in an abrasion wound. The hydrogel also reduced drug leaching and did not promote antibiotic resistance during long-term exposure. The team has patented the material and is working toward further development.
Difficult words
- hydrogel — a soft material made mostly of water
- crosslinker — a molecule that connects polymer chains togethercrosslinkers
- break down — to separate into smaller parts or piecesbreaks down
- enzyme — a protein that speeds up chemical reactionsenzymes
- beta-lactamase — an enzyme many bacteria make that destroys antibioticsbeta-lactamases
- degrade — to become weaker or to be chemically brokendegrades
- antibiotic resistance — when bacteria survive despite antibiotic treatment
Tip: hover, focus or tap highlighted words in the article to see quick definitions while you read or listen.
Discussion questions
- Would you prefer a wound dressing that releases antibiotics only when infection appears? Why or why not?
- What are the benefits of reducing drug leaching from a wound dressing?
- What steps do you think the research team should take next to develop this material further?
Related articles
Most US drug trials do not mirror racial and ethnic diversity
A study of pivotal trials used to approve new drugs found only a small share reflect the United States racial and ethnic makeup. The review shows underrepresentation of Black and Hispanic people and urges more diversity earlier in development.
Brown study suggests targeting mTORC2 could help fight cancer
Researchers at Brown University report that blocking the mTORC2 protein complex, while leaving mTORC1 active, may stop cancer growth signals without triggering survival pathways. The work offers a new direction for designing cancer drugs.
Gagandeep Kang on Vaccines, Surveillance and Child Health in India
Gagandeep Kang, a leading expert on enteric diseases, urges India to prepare tools to prevent viral outbreaks. She helped develop indigenous rotavirus vaccines, built surveillance networks and now works at the Gates Foundation.